These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 32246177)

  • 21. Automatic deep learning multicontrast corpus callosum segmentation in multiple sclerosis.
    Brusini I; Platten M; Ouellette R; Piehl F; Wang C; Granberg T
    J Neuroimaging; 2022 May; 32(3):459-470. PubMed ID: 35083815
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Brain Magnetic Resonance Imaging Volumetric Measures of Functional Outcome after Severe Traumatic Brain Injury in Adolescents.
    Ferrazzano P; Yeske B; Mumford J; Kirk G; Bigler ED; Bowen K; O'Brien N; Rosario B; Beers SR; Rathouz P; Bell MJ; Alexander AL
    J Neurotrauma; 2021 Jun; 38(13):1799-1808. PubMed ID: 33487126
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Disability Improvement Is Associated with Less Brain Atrophy Development in Multiple Sclerosis.
    Ghione E; Bergsland N; Dwyer MG; Hagemeier J; Jakimovski D; Ramasamy DP; Hojnacki D; Lizarraga AA; Kolb C; Eckert S; Weinstock-Guttman B; Zivadinov R
    AJNR Am J Neuroradiol; 2020 Sep; 41(9):1577-1583. PubMed ID: 32763899
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Grey matter atrophy is associated with disability increase in natalizumab-treated patients.
    Ciampi E; Pareto D; Sastre-Garriga J; Vidal-Jordana A; Tur C; Río J; Tintoré M; Auger C; Rovira A; Montalban X
    Mult Scler; 2017 Apr; 23(4):556-566. PubMed ID: 27354019
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Novel Semiautomated Pipeline to Measure Brain Atrophy and Lesion Burden in Multiple Sclerosis: A Long-Term Comparative Study.
    Uher T; Krasensky J; Vaneckova M; Sobisek L; Seidl Z; Havrdova E; Bergsland N; Dwyer MG; Horakova D; Zivadinov R
    J Neuroimaging; 2017 Nov; 27(6):620-629. PubMed ID: 28464417
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cerebrospinal fluid levels of neurofilament and tau correlate with brain atrophy in natalizumab-treated multiple sclerosis.
    Mellergård J; Tisell A; Blystad I; Grönqvist A; Blennow K; Olsson B; Dahle C; Vrethem M; Lundberg P; Ernerudh J
    Eur J Neurol; 2017 Jan; 24(1):112-121. PubMed ID: 27699930
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Brain Atrophy in Natalizumab-treated Patients with Multiple Sclerosis: A 5-year Retrospective Study.
    Eisele P; Szabo K; Ebert A; Platten M; Gass A
    J Neuroimaging; 2019 Mar; 29(2):190-192. PubMed ID: 30485572
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Determination of ventricular diameters in multiple sclerosis patients with transcranial sonography (TCS)--a two year follow-up study.
    Kallmann BA; Sauer J; Schliesser M; Warmuth-Metz M; Flachenecker P; Becker Dagger G; Rieckmann P; Mäurer M
    J Neurol; 2004 Jan; 251(1):30-4. PubMed ID: 14999486
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Two-dimensional measurements with cut-off values are useful for assessing brain volume, physical disability, and processing speed in multiple sclerosis.
    Nishizawa K; Fujimori J; Nakashima I
    Mult Scler Relat Disord; 2022 Mar; 59():103543. PubMed ID: 35078126
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Brain Atrophy Is Associated with Disability Progression in Patients with MS followed in a Clinical Routine.
    Ghione E; Bergsland N; Dwyer MG; Hagemeier J; Jakimovski D; Paunkoski I; Ramasamy DP; Silva D; Carl E; Hojnacki D; Kolb C; Weinstock-Guttman B; Zivadinov R
    AJNR Am J Neuroradiol; 2018 Dec; 39(12):2237-2242. PubMed ID: 30467212
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Changes in brain atrophy indices in patients with relapsing-remitting multiple sclerosis treated with natalizumab.
    Arpín EC; Sobrino TG; Vivero CD; del Campo Amigo Jorrín M; Regal AR; González JP; Bouzas ML
    Neurodegener Dis Manag; 2016; 6(1):5-12. PubMed ID: 26782312
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Appraisal of cerebral atrophy in multiple sclerosis by means of the corpus callosum index].
    Perez-Alvarez AI; Garcia-Rua A; Suarez-Santos P; Castanon-Apilanez M; Ameijide-Sanluis E; Saiz-Ayala A; Meilan-Martinez A; Villafani-Echazu WJ; Gonzalez-Delgado M; Oliva-Nacarino P
    Rev Neurol; 2018 Dec; 67(11):417-424. PubMed ID: 30484274
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Composite MRI measures and short-term disability in patients with clinically isolated syndrome suggestive of MS.
    Bommarito G; Bellini A; Pardini M; Solaro C; Roccatagliata L; Laroni A; Capello E; Mancardi GL; Uccelli A; Inglese M
    Mult Scler; 2018 Apr; 24(5):623-631. PubMed ID: 28394195
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A longitudinal observational study of brain atrophy rate reflecting four decades of multiple sclerosis: a comparison of serial 1D, 2D, and volumetric measurements from MRI images.
    Martola J; Bergström J; Fredrikson S; Stawiarz L; Hillert J; Zhang Y; Flodmark O; Lilja A; Ekbom A; Aspelin P; Wiberg MK
    Neuroradiology; 2010 Feb; 52(2):109-17. PubMed ID: 19774369
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Brain atrophy in natalizumab-treated patients: A 3-year follow-up.
    Sastre-Garriga J; Tur C; Pareto D; Vidal-Jordana A; Auger C; Río J; Huerga E; Tintoré M; Rovira A; Montalban X
    Mult Scler; 2015 May; 21(6):749-56. PubMed ID: 25392330
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 'Importance sampling' in MS: use of diffusion tensor tractography to quantify pathology related to specific impairment.
    Lin X; Tench CR; Morgan PS; Niepel G; Constantinescu CS
    J Neurol Sci; 2005 Oct; 237(1-2):13-9. PubMed ID: 16109428
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cortical and white matter lesion topology influences focal corpus callosum atrophy in multiple sclerosis.
    Platten M; Ouellette R; Herranz E; Barletta V; Treaba CA; Mainero C; Granberg T
    J Neuroimaging; 2022 May; 32(3):471-479. PubMed ID: 35165979
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Corpus callosum atrophy--a simple predictor of multiple sclerosis progression: a longitudinal 9-year study.
    Vaneckova M; Kalincik T; Krasensky J; Horakova D; Havrdova E; Hrebikova T; Seidl Z
    Eur Neurol; 2012; 68(1):23-7. PubMed ID: 22677920
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Corpus callosum index and long-term disability in multiple sclerosis patients.
    Yaldizli O; Atefy R; Gass A; Sturm D; Glassl S; Tettenborn B; Putzki N
    J Neurol; 2010 Aug; 257(8):1256-64. PubMed ID: 20198382
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Monitoring disease activity and progression in primary progressive multiple sclerosis using MRI: sub-voxel registration to identify lesion changes and to detect cerebral atrophy.
    Stevenson VL; Smith SM; Matthews PM; Miller DH; Thompson AJ
    J Neurol; 2002 Feb; 249(2):171-7. PubMed ID: 11985382
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.